Restoration of chemosensitivity by bortezomib: Implications for refractory myeloma

Nature Reviews Clinical Oncology

Volumn 6, Issue 4, 2009, Pages 237-240

  Chim, Chor Sang ^a   Hwang, Yu Yan ^a   Pang, Clara ^a   Shek, Tony W ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOPSY TECHNIQUE; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; EMERGENCY WARD; FEMALE; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; RIB FRACTURE; SALVAGE THERAPY; DOSE RESPONSE; DRUG RESISTANCE; MIDDLE AGED; MULTIPLE MYELOMA; PANCREAS TUMOR; PATHOLOGY; PLEURA TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PANCREATIC NEOPLASMS; PLEURAL NEOPLASMS; PROTEASE INHIBITORS; PYRAZINES; TREATMENT OUTCOME;

EID: 67650189466     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.15     Document Type: Article

References (17)

1. Soutar, R. et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br. J. Haematol. 124, 717-726 (2004).
2. Terpos, E. et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur. J. Haematol. 75, 376-383 (2005).
3. Alegre, A. et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: Clinical results of 280 cases from the spanish Registry. Haematologica 87, 609-614 (2002).
4. Zeiser, R. et al. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 34, 1057-1065 (2004).
5. Damaj, G. et al. Features of extramedullary and extraosseous multiple myeloma: A report of 19 patients from a single center. Eur. J. Haematol. 73, 402-406 (2004).
6. Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: Evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175-187 (2002).
7. Hideshima, T. et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7, 585-598 (2007).
8. Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
9. [No authors listed.] Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J. Clin. Oncol. 16, 3832-3842 (1998).
10. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
11. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005).
12. Oakervee, H. E. et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 129, 755-762 (2005).
13. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103, 3175-3184 (2004).
14. Mitsiades, N. et al. The proteasome inhibitor Ps-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101, 2377-2380 (2003).
15. Case, D. C. Jr. et al. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol). Oncology 42, 137-140 (1985).
16. Mateos, M. V. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 108, 2165-2172 (2006).
17. San Miguel, J. F. et al. MMy-3002: A phase 3 study comparing bortezomib-melphalan-prednisolone (VMP) with melphalanprednisolone (MP) in newly diagnosed multiple myeloma [abstract 76]. Blood (ASH annual meeting abstract) 110, 76 (2007).